Connect Biopharma Holdings Ltd Earnings: Beat on Revenue Despite EPS Miss

Connect Biopharma Holdings Ltd (CNTB) reported mixed first-quarter 2026 results on May 22, delivering a significant revenue beat while missing earnings expectations by a wide margin.

The company posted an adjusted loss of $2.35 per share, falling short of the $1.54 per share loss that analysts had estimated. This represents a negative earnings surprise of 53.05%, indicating substantially higher losses than anticipated.

Revenue performance told a different story, with Connect Biopharma generating $1.17 million in quarterly revenue compared to analyst estimates of $692,926. The $477,074 revenue beat translated to a positive surprise of 68.85%, nearly doubling Wall Street expectations.

The $0.81 per share earnings miss suggests the biotech company faced higher-than-expected operating expenses or research and development costs during the quarter. Meanwhile, the 68.85% revenue outperformance indicates stronger-than-projected product sales or milestone payments.

This article is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results.